About Seattle Genetics
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: SGEN
- CUSIP: 81257810
- Previous Close: $65.68
- 50 Day Moving Average: $60.04
- 200 Day Moving Average: $57.02
- 52-Week Range: $28.32 - $75.36
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -58.71
- P/E Growth: -2.01
- Market Cap: $9.16B
- Outstanding Shares: 141,869,000
- Beta: 2.25
- Net Margins: -33.51%
- Return on Equity: -20.86%
- Return on Assets: -16.21%
Companies Related to Seattle Genetics:
- Current Ratio: 5.92%
- Quick Ratio: 5.35%
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
Where is Seattle Genetics' stock going? Where will Seattle Genetics' stock price be in 2017?
15 brokerages have issued 1-year price objectives for Seattle Genetics' stock. Their predictions range from $38.00 to $80.00. On average, they expect Seattle Genetics' share price to reach $58.85 in the next twelve months.
When will Seattle Genetics announce their earnings?
Seattle Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
HC Wainwright analysts commented, "CVT-301 data may be good start to 2017. ACOR released top-line data from the pivotal study of CVT-301 (pulmonary inhaled levodopa) this morning. The company reported that the 80mg dose (but not the 60mg dose) produced a statistically significant (p=0.009) improvement in the Unified Parkinson’s Diseases Rating Scale Part-3 (UPDRS III) with a placebo-adjusted treatment effect of -3.92 (-9.83 score for CVT-301)." (2/10/2017)
According to Zacks Investment Research, "Seattle Genetics’ sole dependence on a single product – Adcetris – for growth has its inherent risks. A decline in Adcetris sales will hurt the company's top line. The company has a number of candidates in its pipeline, most of which are in the early stages of development. Any hiccup in their development would adversely affect the stock. Moreover, potential competition in the near future put up tough challenges for the company's revenues. Loss estimates are stable ahead its Q4 release. However, the company’s collaboration agreement with Takeda for the global development and commercialization of Adcetris is encouraging. Also, collaborations with companies like AbbVie, Bayer, Roche and Pfizer provide it with funds in the form of upfront, milestone and other payments. The company’s shares have outperformed the Medical-Biomedical/Genetics industry in the past one year." (1/17/2017)
Cowen and Company analysts commented, "SGEN presented updated Phase I data for SGN-LIV1A in mBC this weekend at SABCS." (12/12/2016)
Who owns Seattle Genetics stock?
Seattle Genetics' stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (11.68%), FMR LLC (8.32%), State Street Corp (1.81%), Artisan Partners Limited Partnership (1.54%), Pinnacle Associates Ltd. (0.78%) and Columbia Wanger Asset Management LLC (0.54%). Company insiders that own Seattle Genetics stock include Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Felix Baker, John A Orwin, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes.
Who sold Seattle Genetics stock? Who is selling Seattle Genetics stock?
Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, FMR LLC, Eventide Asset Management LLC, Baillie Gifford & Co., Boxer Capital LLC, Pinnacle Associates Ltd., Allianz Asset Management AG and Guggenheim Capital LLC. Company insiders that have sold Seattle Genetics stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman and Vaughn B Himes.
Who bought Seattle Genetics stock? Who is buying Seattle Genetics stock?
Seattle Genetics' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Two Sigma Investments LP, Renaissance Technologies LLC, Russell Investments Group Ltd., Asset Management One Co. Ltd., Columbia Wanger Asset Management LLC, Janus Capital Management LLC and AQR Capital Management LLC. Company insiders that have bought Seattle Genetics stock in the last two years include Felix Baker and John A Orwin.
How do I buy Seattle Genetics stock?
Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Seattle Genetics stock cost?
One share of Seattle Genetics stock can currently be purchased for approximately $64.58.